VolitionRx to Present Innovative Insights on Nu.Q® Cancer Diagnostics in Upcoming Virtual Event
VolitionRx Limited, a prominent player in the epigenetics sector, is gearing up for an exciting virtual investor event set for April 9, 2025. This ongoing commitment to innovation underlines Volition's mission focused on enhancing early cancer detection through their Nu.Q® platform.
The webinar will commence at 10:00 AM ET, featuring key insights from executives Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter, Chief Medical Officer, and Dr. Jake Micallef, Chief Scientific Officer. They will collectively outline the progress achieved in the commercialization of Volition's groundbreaking diagnostic tools.
Gael Forterre is expected to highlight the advances Volition has made towards bringing its cancer diagnostics to market through both licensing arrangements and direct sales. The focus will shift to Dr. Retter's presentation, which will delve into the Nu.Q® assays' roles in comprehensive lung cancer management—from initial screening to assisting with treatment options during diagnosis and tracking disease progression.
Notably, the Total Annual Accessible Market for lung cancer screening and related prognostics is poised to reach approximately $4 billion, signifying a monumental opportunity for Volition. This strengthens the company's position in the highly competitive oncology diagnostics space.
Dr. Micallef will present groundbreaking research findings, soon to be peer-reviewed, indicating that the Nu.Q® Cancer test effectively detects prevalent cancers, including lung, breast, prostate, colon, and liver cancers, showcasing an impressive overall accuracy (AUC) of 86% and remarkably low false-positive rates.
These findings could revolutionize the manner in which multi-cancer early detection is approached within the U.S. market, which is projected to surpass $20 billion in potential revenue pathways. Following the formal presentations, attendees will engage in a live Q&A session, allowing participants to gain deeper insights into Volition's innovative approaches in cancer diagnostics.
About the featured speakers: Gael Forterre has rapidly risen through the ranks at Volition since joining in 2021 and has a wealth of experience in commercial strategy. Dr. Andrew Retter, whose accolades include a robust career as a consultant in critical care, brings extensive clinical expertise to the event. Lastly, Dr. Jake Micallef, a founding scientist of Volition, has dedicated his career to advancing diagnostics, which underscores the company's commitment to innovation.
Volition's operations primarily take place at its R&D facilities in Belgium, with innovation activities expanding from its U.S. base in Henderson, Nevada, and an increasing presence in London. Through establishing cost-effective blood tests, Volition aims to enhance the early detection and monitoring of various diseases, including several types of cancers and severe conditions like sepsis.
In conclusion, this virtual event is set against the backdrop of rising interest in cancer diagnostics. As the market continues to evolve, VolitionRx is at the forefront of delivering insights into innovations that not only save lives but also enhance the quality of life for numerous patients. This upcoming webinar serves as a critical platform for sharing important developments and positioning Volition as a leader in the healthcare and diagnostics sectors. The company’s aim of transforming medical practices through advanced technologies aligns with a broader movement towards more proactive healthcare solutions.
Investors and stakeholders interested in revolutionary diagnostic technologies should seize this opportunity to learn about the groundbreaking work VolitionRx continues to pursue and the potential impact it may have on cancer diagnostics overall.
The webinar will commence at 10:00 AM ET, featuring key insights from executives Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter, Chief Medical Officer, and Dr. Jake Micallef, Chief Scientific Officer. They will collectively outline the progress achieved in the commercialization of Volition's groundbreaking diagnostic tools.
Gael Forterre is expected to highlight the advances Volition has made towards bringing its cancer diagnostics to market through both licensing arrangements and direct sales. The focus will shift to Dr. Retter's presentation, which will delve into the Nu.Q® assays' roles in comprehensive lung cancer management—from initial screening to assisting with treatment options during diagnosis and tracking disease progression.
Notably, the Total Annual Accessible Market for lung cancer screening and related prognostics is poised to reach approximately $4 billion, signifying a monumental opportunity for Volition. This strengthens the company's position in the highly competitive oncology diagnostics space.
Dr. Micallef will present groundbreaking research findings, soon to be peer-reviewed, indicating that the Nu.Q® Cancer test effectively detects prevalent cancers, including lung, breast, prostate, colon, and liver cancers, showcasing an impressive overall accuracy (AUC) of 86% and remarkably low false-positive rates.
These findings could revolutionize the manner in which multi-cancer early detection is approached within the U.S. market, which is projected to surpass $20 billion in potential revenue pathways. Following the formal presentations, attendees will engage in a live Q&A session, allowing participants to gain deeper insights into Volition's innovative approaches in cancer diagnostics.
About the featured speakers: Gael Forterre has rapidly risen through the ranks at Volition since joining in 2021 and has a wealth of experience in commercial strategy. Dr. Andrew Retter, whose accolades include a robust career as a consultant in critical care, brings extensive clinical expertise to the event. Lastly, Dr. Jake Micallef, a founding scientist of Volition, has dedicated his career to advancing diagnostics, which underscores the company's commitment to innovation.
Volition's operations primarily take place at its R&D facilities in Belgium, with innovation activities expanding from its U.S. base in Henderson, Nevada, and an increasing presence in London. Through establishing cost-effective blood tests, Volition aims to enhance the early detection and monitoring of various diseases, including several types of cancers and severe conditions like sepsis.
In conclusion, this virtual event is set against the backdrop of rising interest in cancer diagnostics. As the market continues to evolve, VolitionRx is at the forefront of delivering insights into innovations that not only save lives but also enhance the quality of life for numerous patients. This upcoming webinar serves as a critical platform for sharing important developments and positioning Volition as a leader in the healthcare and diagnostics sectors. The company’s aim of transforming medical practices through advanced technologies aligns with a broader movement towards more proactive healthcare solutions.
Investors and stakeholders interested in revolutionary diagnostic technologies should seize this opportunity to learn about the groundbreaking work VolitionRx continues to pursue and the potential impact it may have on cancer diagnostics overall.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.